<DOC>
	<DOCNO>NCT01029548</DOCNO>
	<brief_summary>The present study design prospective observational study direct evaluating frequency , magnitude , quality persistence ( primary endpoint ) anti-Tat immune response HIV-1 infect asymptomatic individual , prospectively evaluate immunological , virological clinical outcome anti-Tat positive versus anti-Tat negative drug naїve subject ( secondary endpoint ) order determine impact anti-Tat immunity HIV disease progression well potential use anti-Tat immune response assessment clinical therapeutic management infect patient . This survey provide important information design , plan conduction future therapeutic vaccine trial base HIV-1 Tat protein asymptomatic subject .</brief_summary>
	<brief_title>Observational Study Anti-Tat Immune Response HIV-1-infected Asymptomatic Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>To clinically asymptomatic HIV1 infect individual CD4+ T cell count ≥400/μL To naïve antiretroviral therapy Levels plasma viremia ≤100,000 copies/ml baseline Age ≥ 18 year Signed informed consent Current therapy immunomodulators immunosuppressive drug chemotherapy neoplastic disorder Concomitant treatment HBV HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Therapeutic Vaccine</keyword>
</DOC>